Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

BCG immunotherapy of a rat sarcoma.

R W Baldwin, M V Pimm

    British Journal of Cancer
    |October 1, 1973
    PubMed
    Summary

    Immunotherapy using Bacillus Calmette-Guerin (BCG) with viable tumor cells suppressed sarcoma growth in rats. Early treatment within 4 days was crucial for rejecting up to 10(6) tumor cells, offering insights for human cancer therapy.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Carrier design: new generation of polycationic branched polypeptides containing OH groups with prolonged blood survival and diminished in vitro cytotoxicity.

    Bioconjugate chemistry·1999
    Same author

    Synthesis, conformation, biodistribution, and hormone-related in vitro antitumor activity of a gonadotropin-releasing hormone antagonist-branched polypeptide conjugate.

    Bioconjugate chemistry·1996
    Same author

    Biodistribution in tumour-bearing mice of polycationic, amphoteric and polyanionic branched polypeptides with a poly(L-lysine) backbone labelled with 125I and 111In: tumour accumulation less than that of labelled serum proteins.

    Journal of cancer research and clinical oncology·1996
    Same author

    Gamma scintigraphy of the biodistribution of 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in mice with transplanted melanoma and mammary carcinoma.

    Journal of drug targeting·1996
    Same author

    Gamma scintigraphy of a 123I-labelled N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugate containing galactosamine following intravenous administration to nude mice bearing hepatic human colon carcinoma.

    Journal of drug targeting·1996
    Same author

    Gamma scintigraphy of 111In-labelled branched chain polypeptides (BCP) with a poly(L-lysine) backbone in mice with mammary carcinoma: effect of charge on biodistribution and tumour imaging potential.

    Annals of nuclear medicine·1995

    Area of Science:

    • Oncology
    • Immunology
    • Cancer Research

    Background:

    • Syngeneic tumor models are crucial for studying anti-cancer immune responses.
    • Bacillus Calmette-Guerin (BCG) is an immunotherapy agent with potential in cancer treatment.
    • Understanding optimal conditions for tumor rejection is vital for developing effective immunotherapies.

    Purpose of the Study:

    • To evaluate the efficacy of BCG-mediated immunotherapy in suppressing syngeneic rat sarcoma growth.
    • To determine the maximum tumor cell challenge that can be rejected using this immunotherapy approach.
    • To establish the optimal timing for initiating immunotherapy in relation to tumor cell inoculation.

    Main Methods:

    • Syngeneic rat sarcoma cells were injected in combination with BCG.
    • Tumor rejection was assessed following mixed inocula injection.
    • Simultaneous tumor challenge at a contralateral site was used to evaluate systemic suppression.
    • Viable tumor cells versus radiation-attenuated cells were compared as immunizing stimuli.
    • The maximum number of tumor cells rejected and the time window for effective treatment were determined.

    Main Results:

    • Co-injection of tumor cells with BCG led to the suppression of tumor growth.
    • Rejection of the mixed inoculum conferred resistance to a simultaneous contralateral tumor challenge.
    • Viable tumor cells were more effective immunizing agents than radiation-attenuated cells.
    • The maximum tumor cell challenge completely rejected was approximately 10^6 cells.
    • Effective immunotherapy required initiation within 4 days of tumor cell injection for this rapidly growing sarcoma.

    Conclusions:

    • BCG combined with viable tumor cells can induce rejection of syngeneic tumors and provide systemic protection.
    • The effectiveness of this immunotherapy is dependent on the dose of tumor cells and the timing of treatment initiation.
    • These findings have implications for adjuvant immunotherapy strategies in human cancers, particularly in settings aiming to control minimal residual disease.

    Related Experiment Videos